Bicycle Therapeutics (BCYC) Equity Average (2018 - 2026)

Bicycle Therapeutics has reported Equity Average for 9 years, with the latest figure at $582.1 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 24.07% year-over-year to $582.1 million; the trailing twelve-month figure through Mar 2026 stood at $582.1 million (down 24.07% YoY), and the FY2025 full-year result was $701.5 million, up 20.54% from the prior year.
• Equity Average for Q1 2026 stood at $582.1 million, down from $614.2 million in the prior quarter.
• The five-year high for Equity Average was $852.4 million in Q3 2024, with the low at $231.6 million in Q2 2023.
• Historically, Equity Average has averaged $493.8 million across 5 years, with a median of $393.5 million in 2023.
• Annual changes were most pronounced in 2022 — Equity Average soared 184.79% — and 2023, when it dropped 27.8%.
• Bicycle Therapeutics' Equity Average stood at $280.1 million in 2022, then surged by 40.46% to $393.5 million in 2023, then jumped by 106.38% to $812.0 million in 2024, then decreased by 24.36% to $614.2 million in 2025, then declined by 5.22% to $582.1 million in 2026.
• The last three Equity Average figures came in at $582.1 million (Q1 2026), $614.2 million (Q4 2025), and $643.7 million (Q3 2025), per Business Quant data.